MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$38,213K
Net Income
-$17,494K
Net Profit Margin
-45.78%
EPS
-$0.1
Unit: Thousand (K) dollars
Revenue Breakdown
    • CINVANTI
    • ZYNRELEF
    • Aponvie
    • SUSTOL
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Net product sales
38,213
37,200
38,903
45,342*
Cost of product sales
11,914
9,857
8,457
10,274*
Gross profit
26,299
27,343
30,446
35,068*
Research and development
3,470
2,934
2,279
3,288*
General and administrative
13,980
14,471
12,702
16,278*
Sales and marketing
12,942
11,575
12,311
14,169*
Total operating expenses
30,392
28,980
27,292
33,735*
Gain from operations
-4,093
-1,637
3,154
1,333*
Loss on debt extinguishment
-11,339
-
-
-
Other expense, net
-2,063
-744
-519
108*
Interest expense
-
-
-
1,508*
Interest income
-
-
-
888*
Total other (expense) income, net
-
-
-
-513*
Net gain
-17,495
-2,381
2,635
820
Unrealized gain (loss) on short-term investments
1
-2
-12
-
Comprehensive gain
-17,494
-2,383
2,623
820
Basic EPS
-0.1
-0.02
0.02
0.005
Diluted EPS
-0.1
-0.02
0.01
0.005
Basic Average Shares
170,348,000
154,020,000
153,490,000
152,068,000
Diluted Average Shares
170,348,000
154,020,000
196,921,000
152,068,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive gain-$17,494K (-264.46%↓ Y/Y)Unrealized gain (loss) onshort-term investments$1K (-97.92%↓ Y/Y)CINVANTI$23,955K ZYNRELEF$9,313K Aponvie$3,034K SUSTOL$1,911K Net gain-$17,495K (-260.87%↓ Y/Y)Net product sales$38,213K (16.47%↑ Y/Y)Loss on debtextinguishment-$11,339K Gain from operations-$4,093K (8.19%↑ Y/Y)Other expense, net-$2,063K (-428.97%↓ Y/Y)Gross profit$26,299K (12.62%↑ Y/Y)Cost of product sales$11,914K (25.97%↑ Y/Y)Total operatingexpenses$30,392K (9.28%↑ Y/Y)General andadministrative$13,980K (12.99%↑ Y/Y)Sales and marketing$12,942K (17.95%↑ Y/Y)Research and development$3,470K (-22.28%↓ Y/Y)

HERON THERAPEUTICS, INC. DE (HRTX)

HERON THERAPEUTICS, INC. DE (HRTX)